A genome-wide association study identifies locus at 10q22 associated with clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients in Japanese

Human Molecular Genetics

Volumn 21, Issue 7, 2012, Pages 1665-1672

  Kiyotani, Kazuma ^a   Mushiroda, Taisei ^a   Tsunoda, Tatsuhiko ^a   Morizono, Takashi ^a   Hosono, Naoya ^a   Kubo, Michiaki ^a   Tanigawara, Yusuke ^b   Imamura, Chiyo K ^b   Flockhart, David A ^c   Aki, Fuminori ^d   Hirata, Koichi ^e   Takatsuka, Yuichi ^f   Okazaki, Minoru ^g   Ohsumi, Shozo ^h   Yamakawa, Takashi ⁱ   Sasa, Mitsunori ^j   Nakamura, Yusuke ^a,k   Zembutsu, Hitoshi ^k  

^a RIKEN   (Japan)

^b KEIO UNIVERSITY   (Japan)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Itoh Surgery and Breast Clinic ^*  (Japan)

^e SAPPORO MEDICAL UNIVERSITY   (Japan)

^f KANSAI ROSAI HOSPITAL   (Japan)

^g Sapporo Breast Surgical Clinic   (Japan)

^h NATIONAL HOSPITAL ORGANIZATION SHIKOKU CANCER CENTER   (Japan)

ⁱ Yamakawa Breast Clinic   (Japan)

^j Tokushima Breast Care Clinic   (Japan)

^k THE UNIVERSITY OF TOKYO   (Japan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; CYTOCHROME P450 2D6; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; METHOTREXATE; TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER INVASION; CANCER PATIENT; CANCER SURVIVAL; DRUG RESPONSE; FEMALE; GENE LOCUS; GENETIC ASSOCIATION; GENOTYPE; HUMAN; JAPAN; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CHROMOSOMES, HUMAN, PAIR 10; DISEASE-FREE SURVIVAL; FEMALE; GENETIC LOCI; GENOME-WIDE ASSOCIATION STUDY; HUMANS; JAPAN; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; TAMOXIFEN; TREATMENT OUTCOME;

EID: 84858204909     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddr597     Document Type: Article

References (31)

1. Early Breast Cancer Trialists' Collaborative Group. (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet, 365, 1687-1717.
2. Early Breast Cancer Trialists' Collaborative Group. (1998) Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet, 351, 1451-1467.
3. Borgna, J.L. and Rochefort, H. (1981) Hydroxylated metabolites of tamoxifen are formed in vivo and bound to estrogen receptor in target tissues. J. Biol. Chem., 256, 859-868.
4. Lien, E.A., Solheim, E., Lea, O.A., Lundgren, S., Kvinnsland, S. and Ueland, P.M. (1989) Distribution of 4-hydroxy-N-desmethyltamoxifen and other tamoxifen metabolites in human biological fluids during tamoxifen treatment. Cancer Res., 49, 2175-2183.
5. Johnson, M.D., Zuo, H., Lee, K.H., Trebley, J.P., Rae, J.M., Weatherman, R.V., Desta, Z., Flockhart, D.A. and Skaar, T.C. (2004) Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen. Breast Cancer Res. Treat., 85, 151-159.
6. Kiyotani, K., Mushiroda, T., Sasa, M., Bando, Y., Sumitomo, I., Hosono, N., Kubo, M., Nakamura, Y. and Zembutsu, H. (2008) Impact of CYP2D6*10 on recurrence-free survival in breast cancer patients receiving adjuvant tamoxifen therapy. Cancer Sci., 99, 995-999.
7. Kiyotani, K., Mushiroda, T., Imamura, C.K., Hosono, N., Tsunoda, T., Kubo, M., Tanigawara, Y., Flockhart, D.A., Desta, Z., Skaar, T.C. et al. (2010) Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients. J. Clin. Oncol., 28, 1287-1293.
8. Goetz, M.P., Rae, J.M., Suman, V.J., Safgren, S.L., Ames, M.M., Visscher, D.W., Reynolds, C., Couch, F.J., Lingle, W.L., Flockhart, D.A. et al. (2005) Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J. Clin. Oncol., 23, 9312-9318.
9. Goetz, M.P., Knox, S.K., Suman, V.J., Rae, J.M., Safgren, S.L., Ames, M.M., Visscher, D.W., Reynolds, C., Couch, F.J., Lingle, W.L. et al. (2007) The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res. Treat., 101, 113-121.
10. Schroth, W., Antoniadou, L., Fritz, P., Schwab, M., Muerdter, T., Zanger, U.M., Simon, W., Eichelbaum, M. and Brauch, H. (2007) Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. J. Clin. Oncol., 25, 5187-5193.
11. Lim, H.S., Lee, J.H., Lee, S.K., Lee, S.E., Jang, I.J. and Ro, J. (2007) Clinical implications of CYP2D6 genotypes predictive of tamoxifen pharmacokinetics in metastatic breast cancer. J. Clin. Oncol., 25, 3837-3845.
12. Xu, Y., Sun, Y., Yao, L., Shi, L., Wu, Y., Ouyang, T., Li, J., Wang, T., Fan, Z., Fan, T. et al. (2008) Association between CYP2D6*10 genotype and survival of breast cancer patients receiving tamoxifen treatment. Ann. Oncol., 19, 1423-1429.
13. Jin, Y., Desta, Z., Stearns, V., Ward, B., Ho, H., Lee, K.H., Skaar, T., Storniolo, A.M., Li, L., Araba, A. et al. (2005) CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J. Natl Cancer Inst., 97, 30-39.
14. Gjerde, J., Geisler, J., Lundgren, S., Ekse, D., Varhaug, J.E., Mellgren, G., Steen, V.M. and Lien, E.A. (2010) Associations between tamoxifen, estrogens, and FSH serum levels during steady state tamoxifen treatment of postmenopausal women with breast cancer. BMC Cancer, 10, 313.
15. Schroth, W., Goetz, M.P., Hamann, U., Fasching, P.A., Schmidt, M., Winter, S., Fritz, P., Simon, W., Suman, V.J., Ames, M.M. et al. (2009) Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. J. Am. Med. Assoc., 302, 1429-1436.
16. Wegman, P., Elingarami, S., Carstensen, J., Stal, O., Nordenskjold, B. and Wingren, S. (2007) Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer. Breast Cancer Res., 9, R7.
17. Bejerano, G., Pheasant, M., Makunin, I., Stephen, S., Kent, W.J., Mattick, J.S. and Haussler, D. (2004) Ultraconserved elements in the human genome. Science, 304, 1321-1325.
18. Deloukas, P., Earthrowl, M.E., Grafham, D.V., Rubenfield, M., French, L., Steward, C.A., Sims, S.K., Jones, M.C., Searle, S., Scott, C. et al. (2004) The DNA sequence and comparative analysis of human chromosome 10. Nature, 429, 375-381.
19. Venkatesh, B., Kirkness, E.F., Loh, Y.H., Halpern, A.L., Lee, A.P., Johnson, J., Dandona, N., Viswanathan, L.D., Tay, A., Venter, J.C. et al. (2006) Ancient noncoding elements conserved in the human genome. Science, 314, 1892.
20. Hurtado, A., Holmes, K.A., Geistlinger, T.R., Hutcheson, I.R., Nicholson, R.I., Brown, M., Jiang, J., Howat, W.J., Ali, S. and Carroll, J.S. (2008) Regulation of ERBB2 by oestrogen receptor-PAX2 determines response to tamoxifen. Nature, 456, 663-666.
21. Han, H.J., Russo, J., Kohwi, Y. and Kohwi-Shigematsu, T. (2008) SATB1 reprogrammes gene expression to promote breast tumour growth and metastasis. Nature, 452, 187-193.
22. Heinzen, E.L., Ge, D., Cronin, K.D., Maia, J.M., Shianna, K.V., Gabriel, W.N., Welsh-Bohmer, K.A., Hulette, C.M., Denny, T.N. and Goldstein, D.B. (2008) Tissue-specific genetic control of splicing: implications for the study of complex traits. PLoS Biol, 6, e1.
23. Kiyotani, K., Mushiroda, T., Hosono, N., Tsunoda, T., Kubo, M., Aki, F., Okazaki, Y., Hirata, K., Takatsuka, Y., Okazaki, M. et al. (2010) Lessons for pharmacogenomics studies: association study between CYP2D6 genotype and tamoxifen response. Pharmacogenet. Genomics, 20, 565-568.
24. Rokavec, M., Schroth, W., Amaral, S.M., Fritz, P., Antoniadou, L., Glavac, D., Simon, W., Schwab, M., Eichelbaum, M. and Brauch, H. (2008) A polymorphism in the TC21 promoter associates with an unfavorable tamoxifen treatment outcome in breast cancer. Cancer Res., 68, 9799-9808.
25. Moeder, C.B., Giltnane, J.M., Harigopal, M., Molinaro, A., Robinson, A., Gelmon, K., Huntsman, D., Camp, R.L. and Rimm, D.L. (2007) Quantitative justification of the change from 10% to 30% for human epidermal growth factor receptor 2 scoring in the American Society of Clinical Oncology/College of American Pathologists Guidelines: tumor heterogeneity in breast cancer and its implications for tissue microarray based assessment of outcome. J. Clin. Oncol., 25, 5418-5425.
26. Ohnishi, Y., Tanaka, T., Ozaki, K., Yamada, R., Suzuki, H. and Nakamura, Y. (2001) A high-throughput SNP typing system for genome-wide association studies. J. Hum. Genet., 46, 471-477.
27. Frazer, K.A., Ballinger, D.G., Cox, D.R., Hinds, D.A., Stuve, L.L., Gibbs, R.A., Belmont, J.W., Boudreau, A., Hardenbol, P., Leal, S.M. et al. (2007) A second generation human haplotype map of over 3.1 million SNPs. Nature, 449, 851-861.
28. Barrett, J.C., Fry, B., Maller, J. and Daly, M.J. (2005) Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics, 21, 263-265.
29. Hosono, N., Kato, M., Kiyotani, K., Mushiroda, T., Takata, S., Sato, H., Amitani, H., Tsuchiya, Y., Yamazaki, K., Tsunoda, T. et al. (2009) CYP2D6 genotyping for functional-gene dosage analysis by allele copy number detection. Clin. Chem., 55, 1546-1554.
30. Kiyotani, K., Mushiroda, T., Kubo, M., Zembutsu, H., Sugiyama, Y. and Nakamura, Y. (2008) Association of genetic polymorphisms in SLCO1B3 and ABCC2 with docetaxel-induced leukopenia. Cancer Sci., 99, 967-972.
31. Devlin, B. and Roeder, K. (1999) Genomic control for association studies. Biometrics, 55, 997-1004.